CN115487288A - Almond peptide oral liquid and preparation method thereof - Google Patents
Almond peptide oral liquid and preparation method thereof Download PDFInfo
- Publication number
- CN115487288A CN115487288A CN202211191442.XA CN202211191442A CN115487288A CN 115487288 A CN115487288 A CN 115487288A CN 202211191442 A CN202211191442 A CN 202211191442A CN 115487288 A CN115487288 A CN 115487288A
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- almond peptide
- almond
- freeze
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000011437 Amygdalus communis Nutrition 0.000 title claims abstract description 83
- 241000220304 Prunus dulcis Species 0.000 title claims abstract description 83
- 235000020224 almond Nutrition 0.000 title claims abstract description 83
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 72
- 239000007788 liquid Substances 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 108010028144 alpha-Glucosidases Proteins 0.000 claims abstract description 38
- 239000002105 nanoparticle Substances 0.000 claims abstract description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000008213 purified water Substances 0.000 claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 16
- 101800001442 Peptide pr Proteins 0.000 claims abstract description 13
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 claims abstract description 9
- 239000004386 Erythritol Substances 0.000 claims abstract description 9
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 9
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims abstract description 9
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 9
- 229940009714 erythritol Drugs 0.000 claims abstract description 9
- 235000019414 erythritol Nutrition 0.000 claims abstract description 9
- 235000011187 glycerol Nutrition 0.000 claims abstract description 9
- 239000001814 pectin Substances 0.000 claims abstract description 9
- 229920001277 pectin Polymers 0.000 claims abstract description 9
- 235000010987 pectin Nutrition 0.000 claims abstract description 9
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 9
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 9
- 229960001462 sodium cyclamate Drugs 0.000 claims abstract description 9
- 239000004475 Arginine Substances 0.000 claims abstract description 6
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims abstract 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 24
- 229920001661 Chitosan Polymers 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 21
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 20
- 229940098773 bovine serum albumin Drugs 0.000 claims description 20
- 238000008416 Ferritin Methods 0.000 claims description 19
- 102000008857 Ferritin Human genes 0.000 claims description 18
- 108050000784 Ferritin Proteins 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 17
- 239000000377 silicon dioxide Substances 0.000 claims description 16
- 235000012239 silicon dioxide Nutrition 0.000 claims description 14
- 238000004108 freeze drying Methods 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- 238000009210 therapy by ultrasound Methods 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 7
- 239000008055 phosphate buffer solution Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 27
- 230000005764 inhibitory process Effects 0.000 abstract description 23
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 11
- 239000002245 particle Substances 0.000 abstract description 5
- 239000002244 precipitate Substances 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract description 3
- 238000007710 freezing Methods 0.000 abstract description 3
- 230000008014 freezing Effects 0.000 abstract description 3
- 230000007935 neutral effect Effects 0.000 abstract description 2
- 235000015165 citric acid Nutrition 0.000 abstract 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 33
- 210000004623 platelet-rich plasma Anatomy 0.000 description 28
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 11
- 229940089837 amygdalin Drugs 0.000 description 11
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 11
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 11
- 230000002496 gastric effect Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 6
- 102000038379 digestive enzymes Human genes 0.000 description 6
- 108091007734 digestive enzymes Proteins 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- IFBHRQDFSNCLOZ-IIRVCBMXSA-N 4-nitrophenyl-α-d-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-IIRVCBMXSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000032798 delamination Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960001729 voglibose Drugs 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002114 nanocomposite Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
A preparation method of an almond peptide oral liquid for inhibiting activity of alpha-glucosidase is characterized in that almond peptide nanoparticles, erythritol, glycerol, pectin, citric acid, sodium carboxymethylcellulose, sodium cyclamate and purified water are used, wherein the almond peptide nanoparticles are prepared by embedding almond peptide proline-arginine (PR) and then freezing and drying. The embedding rate is improved by embedding the almond peptide PR with alpha glucosidase activity inhibition, the embedding rate reaches 88.09%, the particle size of the prepared almond peptide nano particles is as small as 105.3nm, the almond peptide nano particles are neutral and stable in oral liquid, the alpha glucosidase activity inhibition performance is effectively kept and not reduced, the stability of the embedded shell is excellent, the phenomenon of falling off and forming precipitate does not occur in pure 24 months, and the stable taste of the oral liquid is ensured. The finally prepared almond peptide oral liquid is digested by gastrointestinal tracts, and the inhibition rate of the almond peptide oral liquid on the activity of alpha glucosidase stably reaches over 64.51 percent.
Description
Technical Field
The invention relates to the technical field of biology, in particular to an almond peptide oral liquid and a preparation method thereof.
Background
Diabetes is a common metabolic disease, and the incidence of diabetes is on the rise worldwide with the increase of living standard and the increase of the elderly population. Diet therapy is the most important and basic treatment measure for various types of diabetes, and the active search for foods which are beneficial to controlling blood sugar from daily diet becomes a hot spot of food science research at present.
Besides reducing blood sugar by insulin, the alpha-glucosidase inhibitor can also be used, and is used for delaying the decomposition and digestion of complex carbohydrate and disaccharide, delaying and reducing the absorption of glucose by intestinal lumen, mainly reducing the postprandial blood sugar effect without affecting the utilization of glucose and the secretion of insulin, can be combined with insulin, and can improve the blood sugar reduction effect by mechanism complementation by inhibiting the glucosidase activity of decomposing oligosaccharide into monosaccharide in small intestinal villus. At present, acarbose, voglibose and the like are common alpha-glucosidase inhibitors, for example, acarbose mainly inhibits alpha-amylase, and voglibose mainly inhibits maltase and sucrase. However, the long-term administration of the medicine can cause nausea, vomiting, anorexia and the like, and can cause abdominal distension, abdominal pain, diarrhea, gastrointestinal spastic pain, intractable constipation and the like. Therefore, many patients with other gastrointestinal diseases, liver and kidney functions and other diseases cannot use the alpha-glucosidase inhibitor, so that the use of the alpha-glucosidase inhibitor is greatly limited.
The semen Armeniacae amarum has biological activities of lowering blood sugar, reducing blood lipid, lowering blood pressure, resisting cancer, etc. The almond can reduce cholesterol, promote cardiovascular health and control blood sugar level when being eaten frequently, and researches show that the almond polypeptide with high dose has the function of inhibiting the reduction of insulin in the aspect of assisting the blood sugar reduction by the bioactive polypeptide. However, there are many routes that can cause blood glucose decline, and the hypoglycemic activity of almond polypeptide has a significant relationship with the structure of the polypeptide. Therefore, the almond peptide with high-efficiency inhibition effect on the alpha-glucosidase is sought, and the almond peptide is prepared into the oral liquid which is convenient to carry and take and is beneficial to the diabetic patients to take.
Disclosure of Invention
The invention aims to provide an almond peptide oral liquid capable of efficiently inhibiting the activity of alpha-glucosidase.
The invention also aims to provide a preparation method of the almond peptide oral liquid.
The purpose of the invention is realized by the following technical scheme:
an almond peptide oral liquid for inhibiting activity of alpha-glucosidase is characterized in that: the almond peptide nano particles are prepared by embedding almond peptide proline-arginine (PR) by adopting bovine serum albumin, ferritin and chitosan, and then freezing and drying.
Further, the almond peptide nano-particles comprise, by mass, 1-2% of erythritol, 0.03-0.04% of glycerol, 0.1-0.3% of pectin, 0.01-0.03% of citric acid, 0.02% of sodium carboxymethylcellulose, 0.03% of sodium cyclamate and the balance of purified water.
Further, the embedding treatment is to sequentially dissolve bovine serum albumin, ferritin and chitosan in a phosphate buffer solution with the pH value of 6 to prepare a mixed solution, standing overnight at 4 ℃, freeze-drying to form freeze-dried powder, heating and preserving heat the freeze-dried powder to form a compound, dissolving the compound in purified water to form a solution, adding silicon dioxide and polyethylene glycol, adjusting the pH value, heating and preserving heat again, cooling, adding almond peptide PR, carrying out ultrasonic treatment under an ice bath condition, finally adjusting the pH value, centrifuging and freeze-drying.
Further, the mass ratio of the chitosan, the ferritin and the bovine serum albumin is 3-5.
Further, the mass ratio of the silicon dioxide to the polyethylene glycol is 2.3-0.6, wherein the silicon dioxide accounts for 2-3% of the mass of the compound.
Further, the heating and heat preservation is to heat the freeze-dried powder to 70-80 ℃ and preserve heat for 48 hours to form a compound.
Further, the above compound is dissolved in purified water to form a solution with a concentration of 2-4mg/mL, the pH is adjusted to 5-6, the solution is heated to 90-100 ℃, and the temperature is maintained for 30min.
Further, the mass ratio of the PR to the freeze-dried powder is 1.
Further, the ultrasonic power of the ultrasonic is 200W, specifically 10s of ultrasonic every 10s, and the total time length is 6-10min.
Further, after the ultrasonic treatment, the pH was adjusted to 4 to 6, and after standing for 10min, the mixture was centrifuged at 3500rpm for 10min.
A preparation method of almond peptide oral liquid for inhibiting activity of alpha-glucosidase is characterized in that: the almond peptide nano particle is prepared by embedding almond peptide proline-arginine (PR) and then freezing and drying.
Further, the almond peptide nano-particles comprise, by mass, 1% of erythritol, 0.03-0.04% of glycerol, 0.1-0.3% of pectin, 0.01-0.03% of citric acid, 0.02% of sodium carboxymethylcellulose, 0.03% of sodium cyclamate and the balance purified water.
Further, the embedding treatment is to sequentially dissolve bovine serum albumin, ferritin and chitosan in a phosphate buffer solution with the pH value of 6 to prepare a mixed solution, to stand overnight at 4 ℃, then freeze-dry to form freeze-dried powder, heat and preserve the heat of the freeze-dried powder to form a compound, then dissolve the compound in purified water to form a solution, add silicon dioxide and polyethylene glycol, adjust the pH value to 5-6, heat and preserve the heat again, add almond peptide PR after cooling, perform ultrasonic treatment under the ice bath condition, finally adjust the pH value to 4-6, and perform freeze-drying after centrifugation.
In the preparation process, the amygdalin PR is directly used as a raw material to be prepared into the oral liquid, the amygdalin PR can be gradually disabled after being stored for a long time in the oral liquid, the inhibition effect on alpha-glucosidase is gradually reduced, and the inhibition effect on the alpha-glucosidase is also reduced when the PR directly enters the gastrointestinal tract. Therefore, the method considers that the almond peptide is firstly embedded and then prepared into the oral liquid, but after the chitosan and the bovine serum albumin are compositely embedded, the shell for embedding the almond peptide gradually falls off in the long-term storage process of the oral liquid, and the almond peptide is deposited in the oral liquid, so that the oral liquid becomes turbid, and the almond peptide is exposed again, and the inhibition effect of the almond peptide on the alpha-glucosidase cannot be ensured for a long time.
According to the invention, the newly added ferritin is compounded with the bovine serum albumin and then compounded with the chitosan, and through the formation of a hydrogen bond effect between the amino group of the bovine serum albumin and the hydroxyl group of the chitosan, the free amino group of the amino acid side chain in the ferritin molecule reacts with the carbonyl group at the reduction end of the chitosan molecule, so that a bovine serum albumin-chitosan-ferritin compound is formed, and the structural stability formed between polysaccharide and protein is further improved. And secondly, adding silicon dioxide and polyethylene glycol, adsorbing the silicon dioxide and chitosan through electrostatic attraction under a specific pH value, and heating and preserving heat to form colloid, so that complete and stable embedding of the almond peptide PR is realized, and the embedding rate is obviously improved. And finally, freeze drying is carried out to further stabilize the embedded structure, the particle size of the prepared almond peptide nano particles is further controlled by combining multiple embedding and freeze drying, and the small particle size ensures that the almond peptide nano particles keep stable characters and are not easy to decompose in aqueous solution for a long time. After the nano particles are formed by embedding, the inhibition effect of the prepared almond peptide PR nano composite particles on alpha-glucosidase is obviously improved compared with PR without embedding. In addition, arginine in PR is basic amino acid, so that the antibacterial performance of chitosan can be further enhanced, and other antibacterial components do not need to be added into oral liquid.
Further, the chitosan, the ferritin and the bovine serum albumin are dissolved in a phosphate buffer solution to prepare a mixed solution with a total mass concentration of 1% according to a mass ratio of 3-5.
Further, the mass ratio of the silica to the polyethylene glycol is 2.3-0.6, wherein the silica accounts for 2-3% of the mass of the compound.
Further, the heating and heat preservation are to heat the freeze-dried powder to 70-80 ℃ and preserve the temperature for 48h to form the compound.
Further, the above compound is dissolved in purified water to form a solution with a concentration of 2-4mg/mL, the pH is adjusted to 5-6, the solution is heated to 90-100 ℃, and the temperature is maintained for 30min.
Further, the mass ratio of the PR to the freeze-dried powder is 1.
Further, the ultrasonic power of the ultrasonic is 200W, specifically 10s of ultrasonic every 10s, and the total time length is 6-10min.
Further, after the ultrasonic treatment, the pH was adjusted to 4 to 6, and after standing for 10min, the mixture was centrifuged at 3500rpm for 10min.
Most particularly, the preparation method of the almond peptide oral liquid for inhibiting the activity of alpha-glucosidase is characterized by comprising the following steps:
step 1: dissolving chitosan, ferritin and bovine serum albumin in a mass ratio of 3-5 to 0.5, dissolving in a phosphate buffer solution with pH of 6 to prepare a mixed solution with a total mass concentration of 1%, standing overnight at 4 ℃, then freeze-drying to form freeze-dried powder, preserving heat of the freeze-dried powder at 70-80 ℃ for 48h to form a compound, dissolving the compound in purified water to form a solution with a concentration of 2-4mg/mL, adding silicon dioxide and polyethylene glycol, adjusting the pH to 4-6, heating to 90-100 ℃, preserving heat for 30min, cooling, adding almond peptide PR, PR and freeze-dried powder in a mass ratio of 1;
step 2: the oral liquid is prepared from 1% of almond peptide nanoparticles, 0.03-0.04% of erythritol, 0.1-0.3% of glycerol, 0.01-0.03% of pectin, 0.02% of citric acid, 0.02% of sodium carboxymethylcellulose, 0.03% of sodium cyclamate and the balance of purified water.
The invention has the following technical effects:
the embedding rate is improved by embedding the almond peptide PR with alpha glucosidase activity inhibition, the embedding rate reaches 88.09%, the particle size of the prepared almond peptide nano particles is as small as 105.3nm, the almond peptide nano particles are neutral and stable in oral liquid, the alpha glucosidase activity inhibition performance is effectively kept and not reduced, the stability of the embedded shell is excellent, the almond peptide PR is pure for 24 months, the phenomenon of falling off and forming sediment turbidity is avoided, and the stable taste of the oral liquid is ensured. The finally prepared almond peptide oral liquid is digested by gastrointestinal tracts, and the inhibition rate of the alpha glucosidase activity stably reaches over 64.51 percent.
Drawings
FIG. 1: the amygdalin nanoparticles prepared in example 3 and comparative example 1 simulated the inhibition rate of α -glucosidase activity after gastrointestinal digestion.
Detailed Description
The present invention is described in detail below by way of examples, it should be noted that the following examples are only for illustrating the present invention and should not be construed as limiting the scope of the present invention, and those skilled in the art can make some insubstantial modifications and variations to the present invention based on the above disclosure.
The almond peptide PR (proline-arginine) used in the invention is synthesized by Siranavir biotechnology limited in China, and the structural formula is as follows:
the purity reaches more than 95 percent.
Through verification of various experiments, the amygdalin PR has an excellent effect of inhibiting the activity of alpha-glucosidase, and the specific steps are as follows:
120. Mu.L of phosphate buffer (pH 6.7, 0.5M), 20. Mu.L of sample solution (gradient of concentration change of 2mg/mL, 4mg/mL, 6mg/mL, 8mg/mL, 10mg/mL and 12mg/mL in this order)50 mu L of alpha-glucosidase (0.5 mu/mL) and 50 mu L of substrate 4-nitrobenzene-beta-d-glucopyranoside (PNPG) are placed in a 96-well plate, reacted for 1h at 37 ℃, and Na is added 2 CO 3 (0.67M) 50. Mu.L of the reaction was stopped, and the absorbance of the solution was measured at 405 nm. Data from three independent experiments were collected. The formula for the inhibition activity calculation is as follows:
wherein Ai is the absorbance of a blank portion of the sample replaced with an equal amount of buffer;
AB is the absorbance of the sample;
AC is the absorbance of the control when the sample and PNPG solution were replaced with equal amounts of buffer.
The in vitro alpha-glucosidase inhibition ability IC of the amygdalin PR is calculated by the formula 50 The value was 19.79. + -. 0.006. Mu.M.
Example 1
A preparation method of an almond peptide oral liquid for inhibiting the activity of alpha-glucosidase comprises the following steps:
step 1: dissolving chitosan, ferritin and bovine serum albumin in a mass ratio of 3.2;
and 2, step: the oral liquid is prepared from 1% of almond peptide nanoparticles, 0.03% of erythritol, 0.3% of glycerol, 0.01% of pectin, 0.02% of citric acid, 0.02% of sodium carboxymethylcellulose, 0.03% of sodium cyclamate and the balance of purified water.
The oral liquid prepared by the embodiment is stored for 24 months at normal temperature, the properties are not changed, the color is uniform and transparent, the taste is stable, and the oral liquid does not have any precipitation and delamination phenomena.
Example 2
A preparation method of almond peptide oral liquid for inhibiting activity of alpha-glucosidase comprises the following steps:
step 1: dissolving chitosan, ferritin and bovine serum albumin at a mass ratio of 5.5, dissolving in a phosphate buffer solution at a pH of 6 to prepare a mixed solution with a total mass concentration of 1%, standing overnight at 4 ℃, freeze-drying to form a freeze-dried powder, preserving heat of the freeze-dried powder at 70 ℃ for 48 hours to form a compound, dissolving the compound in purified water to form a solution with a concentration of 3mg/mL, adding silicon dioxide and polyethylene glycol, adjusting the pH to 6, heating to 95 ℃ and preserving heat for 30min, cooling, adding almond peptide PR, PR and freeze-dried powder at a mass ratio of 1;
step 2: the oral liquid is prepared from 1% of almond peptide nanoparticles, 0.04% of erythritol, 0.3% of glycerol, 0.03% of pectin, 0.02% of citric acid, 0.02% of sodium carboxymethylcellulose, 0.03% of sodium cyclamate and the balance of purified water.
The oral liquid prepared by the embodiment is stored for 24 months at normal temperature, the properties are not changed, the color is uniform and transparent, the taste is stable, and any precipitation and layering phenomena do not occur in the oral liquid.
Example 3
A preparation method of an almond peptide oral liquid for inhibiting the activity of alpha-glucosidase comprises the following steps:
step 1: dissolving chitosan, ferritin and bovine serum albumin in a mass ratio of 4.3;
step 2: the oral liquid is prepared from 1% of almond peptide nanoparticles, 0.04% of erythritol, 0.2% of glycerol, 0.02% of pectin, 0.02% of citric acid, 0.02% of sodium carboxymethylcellulose, 0.03% of sodium cyclamate and the balance of purified water.
The oral liquid prepared by the embodiment is stored for 24 months at normal temperature, the properties are not changed, the color is uniform and transparent, the taste is stable, and the oral liquid does not have any precipitation and delamination phenomena.
Comparative example 1:
compared with example 3, in the scheme, the compound is prepared by replacing ferritin with bovine serum albumin, the mass ratio of chitosan to bovine serum albumin is 4.
When the oral liquid prepared by the embodiment is stored for 12 months in a normal temperature environment, the properties of the oral liquid change, the oral liquid begins to be turbid, and fine precipitates appear on the flat bottom, so that the test is not continued.
Comparative example 2:
compared with example 3, in the scheme, the compound is prepared by substituting ferritin for bovine serum albumin, the mass ratio of chitosan to ferritin is 4.
When the oral liquid prepared by the embodiment is stored for 9 months in a normal-temperature environment, the properties of the oral liquid change, the oral liquid is turbid, and fine precipitates appear on the flat bottom, so that the test is not continued.
Comparative example 3:
in contrast to example 3, in this protocol no pH adjustment was performed or freeze drying was not performed after sonication in step 1, and the remaining steps were in accordance with example 3.
The oral liquid prepared by the scheme is stored for 12 months at normal temperature, the properties of the oral liquid change, the oral liquid is turbid, fine precipitates appear on the flat bottom, and the test is not continued.
In the preparation process of each scheme, 100 mu L of filtrate obtained by centrifuging after ultrasonic treatment is diluted by 10 times, and an ultraviolet spectrophotometer is adopted to measure the embedding rate. The maximum absorbance of the almond peptide at 214nm is obtained through ultraviolet scanning, so the absorbance is measured at 214nm, the concentration of the free almond peptide is obtained through calculation, and the embedding rate is obtained, and the result is shown in table 1.
| Embedding Rate (%) | Nanoparticle size (nm) | Absolute potential (mV) | |
| Example 1 | 86±2.09 | 117.4±2.15 | 11.21±0.97 |
| Example 2 | 84±1.73 | 124.9±3.21 | 10.72±1.05 |
| Example 3 | 87±1.94 | 105.3±5.46 | 11.54±1.34 |
| Comparative example 1 | 70±2.12 | 260.4±6.25 | 6.28±2.23 |
| Comparative example 2 | 68±1.85 | 239.5±4.67 | 4.06±1.19 |
| Comparative example 3 | 76±3.34 | 177.1±4.49 | 8.07±1.26 |
The electric potential reflects the stability of the nano particles to a certain extent, the positive and negative indicate the positive and negative of the charged electric charges, the larger the absolute value of the electric potential is, the higher the stability of the nano particles is, and the better the stability of the properties and performance of the prepared oral liquid is.
The amygdalin PR without any embedding treatment, the amygdalin nanoparticles prepared in example 3 of the present invention, and the amygdalin nanoparticles prepared in comparative example 1 were formulated into solutions of the same concentration, and after simulating in vitro gastrointestinal tract digestion, the change in the α -glucosidase inhibitory activity of the product was measured:
the first step is as follows: simulating the gastrodigestive tract
Regulating pH value of the almond peptide nanoparticle solution to 2.0 with 1mol/L hydrochloric acid, heating in water bath to 37 deg.C, adding pepsin (the addition amount is 5% of almond peptide nanoparticle content), stirring, and performing enzymolysis at constant temperature for 2 hr. In the process, samples are taken at 0 hour, 0.5 hour, 1.0 hour, 1.5 hour and 2.0 hours respectively, immediately put into a boiling water bath to inactivate enzyme for 10min, and after cooling, the alpha-glucosidase inhibitory activity of the samples digested by gastric digestive enzyme is measured.
The second step is that: simulation intestinal digestive tract
After the sample is digested by the enzyme system of the gastric digestive tract for 2 hours, the pH value of the system is adjusted to 7.0 by using 5mol/L NaOH solution. Heating to 37 deg.C, adding trypsin (5% of polypeptide content), stirring, and performing enzymolysis at constant temperature for 2 hr. In the process, samples are taken at 3.0, 4.0, 5.0 and 6.0 hours respectively, the samples are immediately placed in a boiling water bath for enzyme deactivation for 10min, and after cooling, the alpha-glucosidase inhibitory activity of the samples after digestion by gastric digestive enzymes is measured.
The inhibitory activity on alpha-glucosidase after the three samples simulated the digestive process of gastrointestinal digestive enzymes is shown in figure 1. After the three samples enter the stomach and the single PR enters the intestinal tract after being digested by the gastric tract, the inhibition rate of the alpha-glucosidase is obviously reduced, and the free PR is enzymolyzed by digestive enzymes of the intestinal tract, so that the absorption rate is reduced, and the inhibition activity of the alpha-glucosidase is influenced. After the PR nanoparticle solution enters the gastric tract, the embedded PR is released again, and the alpha-glucosidase inhibition rate in the gastric tract is lower than that of the PR alone due to the loss of the embedded PR. However, after entering the stomach, the embedded shell on the surface of the almond peptide PR plays a role in slow release protection, and the PR cannot be subjected to enzymolysis by gastric digestive enzyme, so that the alpha-glucosidase inhibition rate of the nanoparticle solution in the stomach is obviously improved compared with the PR. After the almond peptide nanoparticle enters the intestinal tract, the shell with the nanoparticle is used as a barrier, PR (platelet-rich plasma) is still not degraded by intestinal digestive enzymes, so that the alpha-glucosidase inhibition rate is in a gentle state, the alpha-glucosidase inhibition activity of the almond peptide nanoparticle in the intestinal tract is remarkably enhanced compared with PR, and the alpha-glucosidase inhibition rate of the almond peptide nanoparticle prepared in example 3 is stably up to over 64.51% after the almond peptide nanoparticle is digested by the gastrointestinal tract. However, as can be seen from comparative example 1, the shell formed by compounding single bovine serum albumin with chitosan has a poorer slow-release effect than the shell formed by compounding ferritin and bovine serum albumin with chitosan, and the dissolution rate of the shell is higher, so that the amygdalin PR is exposed more quickly, and the inhibition of the amygdalin PR on alpha-glucosidase tends to decrease to 41.19% within 6h, while the inhibition rate of the amygdalin PR without any embedding on alpha-glucosidase decreases to 39.62% after 6 h.
Claims (10)
1. A preparation method of almond peptide oral liquid for inhibiting activity of alpha-glucosidase is characterized in that: the almond peptide nano particles are prepared from almond peptide proline-arginine (PR) through embedding treatment and freeze drying.
2. The method for preparing an almond peptide oral liquid according to claim 1, wherein the almond peptide oral liquid comprises the following components: according to the mass percentage, the almond peptide nano-particles are 1%, the erythritol is 0.03-0.04%, the glycerol is 0.1-0.3%, the pectin is 0.01-0.03%, the citric acid is 0.02%, the sodium carboxymethylcellulose is 0.02%, the sodium cyclamate is 0.03%, and the balance is purified water.
3. The method for preparing an almond peptide oral liquid according to claim 1 or 2, wherein: the embedding treatment comprises the steps of sequentially dissolving bovine serum albumin, ferritin and chitosan in a phosphate buffer solution with the pH value of 6 to prepare a mixed solution, standing overnight at 4 ℃, freeze-drying to form freeze-dried powder, heating and preserving heat the freeze-dried powder to form a compound, dissolving the compound in purified water to form a solution, adding silicon dioxide and polyethylene glycol, adjusting the pH value to 5-6, heating and preserving heat again, cooling, adding almond peptide PR, carrying out ultrasonic treatment under an ice bath condition, finally adjusting the pH value to 4-6, centrifuging and carrying out freeze-drying.
4. The method for preparing an almond peptide oral liquid according to claim 3, wherein the almond peptide oral liquid comprises the following components: the mass ratio of the chitosan to the ferritin to the bovine serum albumin is (3-5).
5. The method for preparing an almond peptide oral liquid according to claim 3 or 4, wherein the almond peptide oral liquid comprises the following components: the mass ratio of the silicon dioxide to the polyethylene glycol is 2.3-0.6, wherein the silicon dioxide accounts for 2-3% of the mass of the compound.
6. The method of preparing an almond peptide oral liquid of claim 5, wherein: the heating and heat preservation is to heat the freeze-dried powder to 70-80 ℃ and preserve heat for 48h to form the compound.
7. The method of preparing an almond peptide oral liquid of claim 6, wherein: the mass ratio of the PR to the freeze-dried powder is 1.
8. The method of preparing an almond peptide oral liquid of claim 7, wherein: the ultrasonic power of the ultrasonic is 200W, specifically 10s of ultrasonic every 10s, and the total time length is 6-10min.
9. The method of preparing an almond peptide oral liquid of claim 8, wherein: after the ultrasonic treatment, the pH value is adjusted to 4-6, and after standing for 10min, the mixture is centrifuged at 3500rpm for 10min.
10. The preparation method of the almond peptide oral liquid is characterized by comprising the following steps:
step 1: dissolving chitosan, ferritin and bovine serum albumin in a mass ratio of 3-5 to 0.5, dissolving in a pH value of 6, putting into a phosphate buffer solution to prepare a mixed solution with a total mass concentration of 1%, standing overnight at 4 ℃, then freeze-drying to form freeze-dried powder, keeping the temperature of the freeze-dried powder at 70-80 ℃ for 48h to form a compound, dissolving the compound in purified water to form a solution, adding silicon dioxide and polyethylene glycol, adjusting the pH value to 4-6, heating and keeping the temperature, cooling, adding almond peptide PR, PR and freeze-dried powder in a mass ratio of 1 to 3-7, carrying out ultrasonic treatment under ice bath conditions, wherein the specific ultrasonic power is 200W, the ultrasonic treatment lasts 10s every 10s, the total duration is 10min, finally adjusting the pH value to 4-6, centrifuging at 3500rpm for 10min, and then carrying out freeze-drying to form almond peptide nanoparticles, wherein the mass ratio of the silicon dioxide to the polyethylene glycol is 2.3-0.6, and the silicon dioxide accounts for 2-3% of the mass of the compound;
step 2: the oral liquid is prepared from 1% of almond peptide nanoparticles, 0.03-0.04% of erythritol, 0.1-0.3% of glycerol, 0.01-0.03% of pectin, 0.02% of citric acid, 0.02% of sodium carboxymethylcellulose, 0.03% of sodium cyclamate and the balance of purified water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211191442.XA CN115487288B (en) | 2022-09-28 | 2022-09-28 | Almond peptide oral liquid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211191442.XA CN115487288B (en) | 2022-09-28 | 2022-09-28 | Almond peptide oral liquid and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115487288A true CN115487288A (en) | 2022-12-20 |
| CN115487288B CN115487288B (en) | 2024-03-01 |
Family
ID=84472028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211191442.XA Active CN115487288B (en) | 2022-09-28 | 2022-09-28 | Almond peptide oral liquid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115487288B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102048695A (en) * | 2009-08-11 | 2011-05-11 | 南京大学 | Preparation method of protein nanoparticle for in vivo delivery of pharmacologically active agent |
| WO2014118774A1 (en) * | 2013-01-29 | 2014-08-07 | Oshadi Drug Administration Ltd. | Pharmaceutical compositions for oral treatment of diabetes |
| CN107698659A (en) * | 2017-11-14 | 2018-02-16 | 重庆三峡学院 | Wild almond protein sources ɑ Glucosidase inhibitor peptides through protease M enzymolysis and preparation method thereof |
| US20180116963A1 (en) * | 2016-10-28 | 2018-05-03 | Zhejiang Academy Of Forestry | Method of preparing albumin nanoparticle carrier wrapping taxane drug |
| WO2021232614A1 (en) * | 2020-05-22 | 2021-11-25 | 广东药科大学 | Chitooligosaccharide oral liquid and application therefor in preparation of weight loss drugs |
| CN115093456A (en) * | 2022-04-24 | 2022-09-23 | 山东省农业科学院 | Almond polypeptide with antioxidant activity and extraction method and application thereof |
-
2022
- 2022-09-28 CN CN202211191442.XA patent/CN115487288B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102048695A (en) * | 2009-08-11 | 2011-05-11 | 南京大学 | Preparation method of protein nanoparticle for in vivo delivery of pharmacologically active agent |
| WO2014118774A1 (en) * | 2013-01-29 | 2014-08-07 | Oshadi Drug Administration Ltd. | Pharmaceutical compositions for oral treatment of diabetes |
| US20180116963A1 (en) * | 2016-10-28 | 2018-05-03 | Zhejiang Academy Of Forestry | Method of preparing albumin nanoparticle carrier wrapping taxane drug |
| CN107698659A (en) * | 2017-11-14 | 2018-02-16 | 重庆三峡学院 | Wild almond protein sources ɑ Glucosidase inhibitor peptides through protease M enzymolysis and preparation method thereof |
| WO2021232614A1 (en) * | 2020-05-22 | 2021-11-25 | 广东药科大学 | Chitooligosaccharide oral liquid and application therefor in preparation of weight loss drugs |
| CN115093456A (en) * | 2022-04-24 | 2022-09-23 | 山东省农业科学院 | Almond polypeptide with antioxidant activity and extraction method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| YU-PING HUANG等: "A complete workflow for discovering small bioactive peptides in foods by LC-MS/MS: A case study on almonds", FOOD CHEMISTRY, 11 August 2021 (2021-08-11), pages 130834 * |
| 顾欣等: "山杏仁蛋白源α-葡萄糖苷酶抑制肽的分离、纯化及鉴定", 中国粮油学报, vol. 31, no. 8, 31 August 2016 (2016-08-31), pages 116 - 121 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115487288B (en) | 2024-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4476566B2 (en) | Soluble highly branched glucose polymer and process for its production | |
| CN111887370A (en) | Uric acid-reducing ocean fish oligopeptide-chitosan oligosaccharide solid beverage | |
| EP2266582B1 (en) | Pharmaceutical composition for preventing dysbiosis associated with enteral administration of antibiotics | |
| CN110801024A (en) | Polysaccharide composite polypeptide for reducing blood sugar, blood fat and glycosylated hemoglobin and preparation method thereof | |
| CN115404252A (en) | Auricularia auricula polysaccharide and application and preparation method thereof | |
| CN114032273B (en) | Multifunctional American ginseng hydrolytic peptide and preparation method and application thereof | |
| CN113693237A (en) | Novel natural solid intervention agent for intervening lactose intolerance diarrhea, preparation method and application | |
| CN114377037A (en) | Composition of lactobacillus paracasei LC-37 and application thereof in reducing blood sugar | |
| CN108113002B (en) | Meal accompanying powder for reducing blood sugar response and fat absorption and preparation method thereof | |
| CN114214366A (en) | Compound medicine of small peptide powder and heme peptide red for preventing and treating anemia and preparation method and application thereof | |
| CN115487288A (en) | Almond peptide oral liquid and preparation method thereof | |
| CN115895966B (en) | Bifidobacterium bifidum BL002 for assisting in relieving gout and application thereof | |
| CN111406935A (en) | Carbohydrate component formula food suitable for preoperative taking and having special medical application and application thereof | |
| KR20210012979A (en) | Levan-protein nanocomposite and uses thereof | |
| JP6571298B2 (en) | Glycemic spike inhibitor, food, and method for producing blood glucose spike inhibitor | |
| JP2006298779A (en) | Antiallergic agent obtained by culture of lactic acid bacterium | |
| JPH08291192A (en) | Lactonized oligosaccharide, its production and alpha amylase inhibitor | |
| CN100394923C (en) | Application of low molecular citrus pectin in regulation of blood sugar, blood fat and improvement of fatty liver | |
| JPWO2015098474A1 (en) | Serum uric acid lowering agent containing rice protein as active ingredient | |
| KR100547169B1 (en) | A composition containing fermented Inonotus Obliquus for preventing and treating diabetes | |
| CN114403450B (en) | Application of auricularia auricula polysaccharide additive in inhibiting generation of metabolic odor of organism | |
| CN116687001B (en) | Phycocyanin-tannic acid-probiotics carrier, preparation method thereof and nutrition | |
| KR101879648B1 (en) | Method for manufacturing fermentation dietary fiber | |
| CN114848601B (en) | Guava leaf extract effervescent tablet and preparation method and application thereof | |
| CN107929292B (en) | Enteral nutrition preparation combining konjac mannan-oligosaccharide and L-glutamine and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |